These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26546219)

  • 1. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
    Johannes JW; Almeida L; Daly K; Ferguson AD; Grosskurth SE; Guan H; Howard T; Ioannidis S; Kazmirski S; Lamb ML; Larsen NA; Lyne PD; Mikule K; Ogoe C; Peng B; Petteruti P; Read JA; Su N; Sylvester M; Throner S; Wang W; Wang X; Wu J; Ye Q; Yu Y; Zheng X; Scott DA
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5743-7. PubMed ID: 26546219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
    Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
    Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
    Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
    Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
    Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
    Wang Z; Grosskurth SE; Cheung T; Petteruti P; Zhang J; Wang X; Wang W; Gharahdaghi F; Wu J; Su N; Howard RT; Mayo M; Widzowski D; Scott DA; Johannes JW; Lamb ML; Lawson D; Dry JR; Lyne PD; Tate EW; Zinda M; Mikule K; Fawell SE; Reimer C; Chen H
    Cancer Res; 2018 Dec; 78(23):6691-6702. PubMed ID: 30297535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
    Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
    Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
    Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
    J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
    Gu C; Lamb ML; Johannes JW; Sylvester MA; Eisman MS; Harrison RA; Hu H; Kazmirski S; Mikule K; Peng B; Su N; Wang W; Ye Q; Zheng X; Lyne PD; Scott DA
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4775-4780. PubMed ID: 27578247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
    Papeo G; Posteri H; Borghi D; Busel AA; Caprera F; Casale E; Ciomei M; Cirla A; Corti E; D'Anello M; Fasolini M; Forte B; Galvani A; Isacchi A; Khvat A; Krasavin MY; Lupi R; Orsini P; Perego R; Pesenti E; Pezzetta D; Rainoldi S; Riccardi-Sirtori F; Scolaro A; Sola F; Zuccotto F; Felder ER; Donati D; Montagnoli A
    J Med Chem; 2015 Sep; 58(17):6875-98. PubMed ID: 26222319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment.
    Li J; Zhou N; Cai P; Bao J
    Int J Mol Sci; 2016 Feb; 17(2):258. PubMed ID: 26907257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of selective inhibition of human tankyrases.
    Narwal M; Venkannagari H; Lehtiö L
    J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
    Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
    J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
    Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
    J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
    Gohlke BO; Overkamp T; Richter A; Richter A; Daniel PT; Gillissen B; Preissner R
    BMC Bioinformatics; 2015 Sep; 16():308. PubMed ID: 26403354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells.
    Castiel A; Visochek L; Mittelman L; Dantzer F; Izraeli S; Cohen-Armon M
    BMC Cancer; 2011 Sep; 11():412. PubMed ID: 21943092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
    Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
    Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors.
    Arnold MR; Langelier MF; Gartrell J; Kirby IT; Sanderson DJ; Bejan DS; Šileikytė J; Sundalam SK; Nagarajan S; Marimuthu P; Duell AK; Shelat AA; Pascal JM; Cohen MS
    Cell Chem Biol; 2022 Dec; 29(12):1694-1708.e10. PubMed ID: 36493759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.